🔎 Trials Near Me

Home › Steatotic Liver Disease › Texas › San Antonio

Steatotic Liver Disease clinical trials in San Antonio, TX

17 studies for Steatotic Liver Disease are looking for participants at sites in and around San Antonio (within about 30 miles). Open a study to see who can join and how to contact the study team.

Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →

A Study to Evaluate the Efficacy and Safety of Pegozafermin in Participants With Compensated Cirrhosis Due to MASH

RecruitingPhase 3
  • 89bio Clinical Study Site, San Antonio
  • 89bio Clinical Study Site, San Antonio
  • 89bio Clinical Study Site, San Antonio
Ages 18 to 75 · All sexes · Updated Oct 5, 2026 · NCT06419374

A Study Evaluating the Efficacy and Safety of Pegozafermin in Participants With MASH and Fibrosis (ENLIGHTEN-Fibrosis)

RecruitingPhase 3
  • 89bio Clinical Study Site, San Antonio
  • 89bio Clinical Study Site, San Antonio
  • 89bio Clinical Study Site, San Antonio
  • and 2 more
Ages 18 to 80 · All sexes · Updated Oct 5, 2026 · NCT06318169

A Study to Investigate Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

RecruitingPhase 3
  • GSK Investigational Site, San Antonio
  • GSK Investigational Site, San Antonio
Ages 18 to 75 · All sexes · Updated Sep 30, 2026 · NCT07704892

A Pivotal Clinical Study to Investigate the Safety and Efficacy of Efimosfermin Compared With Placebo in Adult Participants With Compensated Cirrhosis Due to Metabolic Dysfunction-associated Steatohepatitis (MASH)

RecruitingPhase 3
  • GSK Investigational Site, San Antonio
  • GSK Investigational Site, San Antonio
Ages 18 to 75 · All sexes · Updated Sep 30, 2026 · NCT07701993

A Phase 2a Study of ALN-PNP With and Without a GLP1R Agonist in Adult Patients With Homozygous PNPLA3-Related MASLD

RecruitingPhase 2
  • American Research Corporation at The Texas Liver Institute, San Antonio
Ages 18 to 75 · All sexes · Updated Sep 29, 2026 · NCT07527910

A Precision Medicine Approach Using Gene Silencing to Treat a Chronic Liver Disease Called Metabolic Dysfunction-Associated Steatohepatitis (MASH) in Adult Participants at Increased Genetic Risk for This Condition

RecruitingPhase 2
  • American Research Corporation at The Texas Liver Institute, San Antonio
  • Pinnacle Clinical Research - San Antonio, San Antonio
Ages 18 to 75 · All sexes · Updated Sep 25, 2026 · NCT05519475

A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes)

RecruitingPhase 3
  • American Research Corporation at Texas Liver Institute, San Antonio
  • Clinical Trials of Texas, LLC dba Flourish Research, San Antonio
  • IMA Clinical Research San Antonio, San Antonio
  • and 1 more
Ages 18 and older · All sexes · Updated Sep 22, 2026 · NCT07165028

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

RecruitingPhase 3
  • Akero Clinical Study Site, San Antonio
  • Akero Clinical Study Site, San Antonio
  • Akero Clinical Study Site, San Antonio
  • and 2 more
Ages 18 to 80 · All sexes · Updated Sep 21, 2026 · NCT06528314

A Clinical Study to Investigate the Safety and Tolerability of Efimosfermin Alfa Injection in Participants With Known or Suspected F2- or F3-stage MASH

RecruitingPhase 3
  • GSK Investigational Site, San Antonio
  • GSK Investigational Site, San Antonio
  • GSK Investigational Site, San Antonio
Ages 18 to 75 · All sexes · Updated Sep 17, 2026 · NCT07221188

A Study of a Thyroid Hormone Receptor Beta Isoform (THRβ) Agonist and an Semicarbazide Sensitive Amine Oxidase (SSAO) Inhibitor, Alone and in Combination, in Adults With Presumed Metabolic Dysfunction-associated Steatohepatitis (MASH)

RecruitingPhase 2
  • Quality Research, Inc., San Antonio
  • Pinnacle Clinical Research - South San Antonio, San Antonio
  • Pinnacle Clinical Research, San Antonio
Ages 18 to 75 · All sexes · Updated Sep 9, 2026 · NCT07288138

Quantifying Hepatic Mitochondrial Fluxes in Humans

RecruitingPhase 4
  • Texas Diabetes Institute - University Health System, San Antonio
  • University of Texas Health Science Center at San Antonio, San Antonio
Ages 18 to 80 · All sexes · Updated Aug 17, 2026 · NCT05305287

A Study to Investigate the Safety and Efficacy of GSK4532990 Compared With Placebo in Adult Participants Aged 18 to 70 Years With Alcohol-related Liver Disease

RecruitingPhase 2
  • GSK Investigational Site, San Antonio
Ages 18 to 70 · All sexes · Updated Aug 3, 2026 · NCT06613698

A Pivotal Clinical Study to Investigate Efimosfermin Alfa in Participants With Biopsy-confirmed F2- or F3-stage MASH

RecruitingPhase 3
  • GSK Investigational Site, San Antonio
  • GSK Investigational Site, San Antonio
  • GSK Investigational Site, San Antonio
Ages 18 to 75 · All sexes · Updated Jul 27, 2026 · NCT07221227

A Study of Efimosfermin Alfa in Participants With Biopsy-confirmed Cirrhosis (Compensated) Due to MASH

RecruitingPhase 2
  • GSK Investigational Site, San Antonio
  • GSK Investigational Site, San Antonio
Ages 18 to 75 · All sexes · Updated Jul 8, 2026 · NCT06920043

A Study of Efimosfermin Alfa in Adults With Hepatic Impairment

RecruitingPhase 1
  • GSK Investigational Site, San Antonio
Ages 18 to 70 · All sexes · Updated Jun 9, 2026 · NCT07358546

Evaluating the Pharmacokinetics and Safety of Miricorilant

RecruitingPhase 1
  • Site# 433, San Antonio
Ages 18 to 75 · All sexes · Updated May 26, 2026 · NCT07553663

Evaluation of Non-Invasive Tests for Metabolic Liver Disease

RecruitingObservational study
  • Endeavor Clinical Trials, San Antonio
Ages 18 to 75 · All sexes · Updated Aug 14, 2025 · NCT07122700

About Steatotic Liver Disease

Steatotic liver disease, formerly called fatty liver disease, happens when too much fat builds up in your liver. Learn about the causes and treatments.

More about Steatotic Liver Disease on MedlinePlus

Steatotic Liver Disease trials in other cities

Other studies in San Antonio

From ClinicalTrials.gov, data retrieved Oct 6, 2026. Each study sets its own eligibility; the study team decides who can join.